Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents

Expert Opinion on Biological Therapy

Volumn 14, Issue 7, 2014, Pages 955-967

  Tosti, Giulio ^a   Cocorocchio, Emilia ^a   Pennacchioli, Elisabetta ^a   Ferrucci, Pier Francesco ^a   Testori, Alessandro ^a   Martinoli, Chiara ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Heat shock protein; Immunotherapy; Melanoma

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; CANCER VACCINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; FREUND ADJUVANT; GP100 PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BASED PEPTIDE COMPLEX VACCINE; IMATINIB; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; NILOTINIB; NIVOLUMAB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PEPTIDE VACCINE; POLYVALENT VACCINE; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; SORAFENIB; TAXANE DERIVATIVE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VITESPEN; IMMUNOLOGIC FACTOR; PEPTIDE;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ADVANCED MELANOMA; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; CUTANEOUS MELANOMA; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; MUTATION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER; TUMOR VOLUME; VACCINATION; BIOLOGICAL MODEL; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; IMMUNOLOGY; KIDNEY NEOPLASMS; PATHOLOGY; SKIN NEOPLASMS;

BRAIN NEOPLASMS; CANCER VACCINES; CARCINOMA, RENAL CELL; GLIOBLASTOMA; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MELANOMA; MODELS, BIOLOGICAL; PEPTIDES; SKIN NEOPLASMS;

EID: 84902194486     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.902928     Document Type: Review

References (126)

1. Abdel-Malek ZA, Kadekaro AL, Swope VB. Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res 2010;23(2):171-86
2. Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953- 2008 are recent generations at higher or lower risk? Int J Cancer 2013;132(2):385-400
3. Lipsker D, Engel F, Cribier B, et al. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol 2007;157(2):338-43
4. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383(9919):816-27
5. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
6. di Pietro A, Tosti G, Ferrucci PF, Testori A. The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. Expert Opin Biol Ther 2011;11(10):1395-407
7. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19(2):121-7
8. Kawakami Y, Wang X, Shofuda T, et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumorinfiltrating T lymphocytes. J Immunol 2001;166(4):2871-7
9. Rivoltini L, Castelli C, Carrabba M, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003;171(7):3467-74
10. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100(11):2014-21
11. Kirkwood JM, Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin Oncol 1985;12(4 Suppl 5):7-12
12. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa- 2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444-58
13. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2- KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80
14. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
15. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16
16. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40(12):1825-36
17. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340-6
18. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sundamaged skin. J Clin Oncol 2013;31(26):3182-90
19. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29(21):2904-9
20. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27(17):2823-30
21. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
22. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65
23. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2011;71(23):7137-40
24. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
25. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94
26. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7(2):95-106
27. Kaehler KC, Piel S, Livingstone E. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010;37(5):485-98
28. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
29. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26): 2517-26
30. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27(1):111-22
31. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
32. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
33. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44
34. Ferrucci PF, Tosti G, di Pietro A. Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment. Curr Top Med Chem 2012;12(1):11-31
35. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007;25(Suppl 2):B4-16
36. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11(1):24-37
37. Linette GP, Carreno BM. Dendritic cellbased vaccines: shining the spotlight on signal 3. Oncoimmunology 2013;2(11):e26512
38. Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006;211:81-92
39. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013;123(8):3383-94
40. Hanna MG Jr, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 1978;42(6):2613-25
41. Key ME, Brandhorst JS, Hanna MG Jr. Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer. J Immunol 1983;130(6):2987-92
42. Peters LC, Brandhorst JS, Hanna MG Jr. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979;39(4):1353-60
43. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006;12(7 Pt 2):2337s-41s
44. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364(22):2119-27
45. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013;104(1):15-21
46. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61(17):6451-8
47. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4(3):328-32
48. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17(4):563-70
49. Thurner B, Haendle I, Röder C, et al. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190(11):1669-78
50. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994;152(11):5398-403
51. Ritossa P. [Problems of prophylactic vaccinations of infants]. Riv Ist Sieroter Ital 1962;37:79-108
52. Lewis M, Helmsing PJ, Ashburner M. Parallel changes in puffing activity and patterns of protein synthesis in salivary glands of Drosophila. Proc Natl Acad Sci USA 1975;72(9):3604-8
53. Kampinga HH, Hageman J, Vos MJ. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009;14(1):105-11
54. Tytell M, Greenberg SG, Lasek RJ. Heat shock-like protein is transferred from glia to axon. Brain Res 1986;363(1):161-4
55. Hightower LE, Guidon PT Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol 1989;138(2):257-66
56. Multhoff G, Hightower LE. Distinguishing integral and receptorbound heat shock protein 70 (Hsp70) on the cell surface by Hsp70-specific antibodies. Cell Stress Chaperones 2011;16(3):251-5
57. De Maio A. Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. Cell Stress Chaperones 2011;16(3):235-49
58. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988;22:631-77
59. Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2013;332(2):275-85
60. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986;83(10):3407-11
61. Ullrich SJ, Robinson EA, Law LW, et al. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci USA 1986;83(10):3121-5
62. Moore SK, Kozak C, Robinson EA, et al. Cloning and nucleotide sequence of the murine hsp84 cDNA and chromosome assignment of related sequences. Gene 1987;56(1):29-40
63. Mazzarella RA, Green M. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem 1987;262(18):8875-83
64. Maki RG, Old LJ, Srivastava PK. Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci USA 1990;87(15):5658-62
65. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178(4):1391-6
66. Srivastava PK, Menoret A, Basu S, et al. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8(6):657-65
67. Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. Embo J 1993;12(8):3143-51
68. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994;91(8):3077-81
69. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278(5335):117-20
70. Yedavelli SP, Guo L, Daou ME, et al. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 1999;4(3):243-8
71. Kovalchin JT, Murthy AS, Horattas MC, et al. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun 2001;1:7
72. Sato K, Torimoto Y, Tamura Y, et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 2001;98(6):1852-7
73. Lammert E, Arnold D, Nijenhuis M, et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 1997;27(4):923-7
74. Spee P, Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 1997;27(9):2441-9
75. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999;162(3):1303-9
76. Arnold-Schild D, Hanau D, Spehner D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999;162(7):3757-60
77. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1(2):151-5
78. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14(3):303-13
79. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17(3):353-62
80. Matsutake T, Sawamura T, Srivastava PK. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun 2010;10:7
81. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269(5230):1585-8
82. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191(11):1965-74
83. Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000;191(11):1957-64
84. Kurotaki T, Tamura Y, Ueda G, et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol 2007;179(3):1803-13
85. Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61(1):222-7
86. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169(10):5424-32
87. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6(4):435-42
88. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277(17):15028-34
89. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277(17):15107-12
90. Vabulas RM, Braedel S, Hilf N. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002;277(23):20847-53
91. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 2002;158(7):1277-85
92. Berwin B, Hart JB, Nicchitta CV, et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. Embo J 2003;22(22):6127-36
93. Singh-Jasuja H, Scherer HU, Hilf N, et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000;30(8):2211-15
94. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12(11):1539-46
95. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 2000;165(11):6029-35
96. Kuppner MC, Gastpar R, Gelwer S, et al. The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 2001;31(5):1602-9
97. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 2001;15(6):971-83
98. Chen W, Syldath U, Bellmann K, et al. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 1999;162(6):3212-19
99. Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J Immunol 2002;168(6):2997-3003
100. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukoc Biol 2009;85(6):905-10
101. Binder RJ, Zhou YJ, Messmer MN, et al. CD91-dependent modulation of immune responses by heat shock proteins: a role in autoimmunity. Autoimmune Dis 2012;2012:863041
102. Multhoff G, Mizzen L, Winchester CC, et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp Hematol 1999;27(11):1627-36
103. Pilla L, Squarcina P, Coppa J, et al. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumorderived heat shock protein 96. Cancer Res 2005;65(9):3942-9
104. Elsner L, Muppala V, Gehrmann M, et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007;179(8):5523-33
105. Radsak MP, Hilf N, Singh-Jasuja H, et al. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 2003;101(7):2810-15
106. Nicchitta CV. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr Opin Immunol 1998;10(1):103-9
107. Huang XF, Ren W, Rollins L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res 2003;63(21):7321-9
108. Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88(2):232-8
109. Eton O, Ross MI, East MJ, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med 2010;8:9
110. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20(20):4169-80
111. Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006;55(8):958-68
112. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26(6):955-62
113. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145- 54
114. Zhang Y, Zheng L. Tumor immunotherapy based on tumor-derived heat shock proteins (Review). Oncol Lett 2013;6(6):1543-9
115. Mazzaferro V, Coppa J, CarrabbaMG, et al. Vaccination with autologous tumorderived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9(9):3235-45
116. Oki Y, Younes A. Heat shock proteinbased cancer vaccines. Expert Rev Vaccines 2004;3(4):403-11
117. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24(29):4738-45
118. Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009;15(10):3495-502
119. Jonasch E, Wood C, Tamboli P, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 2008;98(8):1336-41
120. Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007;52(8):1964-72
121. Dong J, Wei J. Effective vaccines of autologous cancer-derived heat shock protein gp70-complexes in patients with cancer malignancies (pancreatic carcinoma, colo-rectal cancer). Proc Am Soc Clin Oncol (ASCO) 2005;23:2591
122. Li Z, Zeng Y, Katsanis E. An autologous tumor derived heat shock protein vaccine for high risk ovarian cancer. Proc Am Soc Clin Oncol (ASCO) 2005;23:9592
123. Heike M. Pilot trial of vaccination with tumour-derived Gp-96 Heat Shock Protein Peptide Complex (HSPPC-96) in patients after surgery for gastric cancer. Proc Am Soc Clin Oncol 2000;41:3463
124. Hertkorn C, Lehr A, Woelfel T, et al. Phase I trial of vaccination with autologous-tumor derived gp96 (oncophage) in patients after surgery for gastric cancer. Proc Am Soc Clin Oncol 2002;21:117
125. Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 2013;19(1):205-14
126. Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014;16(2):274-9